Mesenchymal Stem Cell–Platelet Aggregates Increased in the Peripheral Blood of Patients with Acute Myocardial Infarction and Might Depend on the Stromal Cell-Derived Factor 1/CXCR4 Axis

2019 ◽  
Vol 28 (24) ◽  
pp. 1607-1619 ◽  
Author(s):  
Ya-Li Song ◽  
Hong Jiang ◽  
Neng-Gang Jiang ◽  
Yong-Mei Jin ◽  
Ting-Ting Zeng
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Peripheral Blood ◽  
Stromal Cell ◽  
Platelet Aggregates ◽  
Stromal Cell Derived Factor ◽  
Cxcr4 Axis

scholarly journals Statin Administration Does Not Improve the Mobilization of Very Small Embryonic-Like Stem Cells (VSELs) in Contrast to Resveratrol Treatment in a Murine Model of Acute Myocardial Infarction

2012 ◽  
pp. 543-549 ◽  
Author(s):  
H. WANG ◽  
Y.-J. YANG ◽  
H.-Y. QIAN ◽  
Q. ZHANG ◽  
L.-J. GAO ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Stem Cell ◽  
Cardiac Function ◽  
Stromal Cell ◽  
Statin Treatment ◽  
Positive Control ◽  
Short Term ◽  
Cellular Cardiomyoplasty ◽  
Stromal Cell Derived Factor

We have found that short-term statin treatment plus stem cell transplantation in acutely infarcted hearts improves cardiac function because statins promote the efficacy of cellular cardiomyoplasty. Autologous Sca-1+Lin-CD45-(CXCR+) very small embryonic-like stem cell (VSEL) mobilization in acute myocardial infarction (AMI) correlates with the preservation of cardiac function. Whether short-term atorvastatin (Ator) can enhance the mobilization or recruitment of VSELs in AMI is still unclear. We divided mice into 4 groups: 1) sham; 2) AMI; 3) AMI+resveratrol (RSV) as a positive control; and 4) AMI+Ator. There was an increase in the circulating VSEL/full population of leukocytes (FPL) ratio 48 hours after AMI, and AMI+RSV increased it further. Ator administration did not increase the VSEL/FPL ratio. The cardiac stromal cell-derived factor-1 (SDF-1) and SDF-1α levels were in agreement with the results of VSEL mobilization. One week after AMI, more Sca-1+CXCR+ cells were recruited to the myocardium of AMI+RSV mice but not AMI+Ator mice. Short-term Ator administration failed to upregulate cardiac SDF-1 and could not enhance the recruitment of VSELs early after AMI.

scholarly journals Stromal cell-derived factor-1/CXC chemokine receptor 4 axis in injury repair and renal transplantation

2019 ◽  
Vol 47 (11) ◽  
pp. 5426-5440
Author(s):  
Zejia Sun ◽  
Xin Li ◽  
Xiang Zheng ◽  
Peng Cao ◽  
Baozhong Yu ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Stromal Cell ◽  
Tissue Injury ◽  
Cxc Chemokine Receptor 4 ◽  
Cxc Chemokine ◽  
Stromal Cell Derived Factor ◽  
Chemokine Receptor 4 ◽  
Cxcr4 Axis

Stem cell therapy has shown promise in treating a variety of pathologies, such as myocardial infarction, ischaemic stroke and organ transplantation. The stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor-4 (CXCR4) axis plays a key role in stem cell mobilization. This review describes the important role of SDF-1 in tissue injury and how it works in tissue revascularization and regeneration via CXCR4. Furthermore, factors influencing the SDF-1/CXCR4 axis and its clinical potential in ischaemia reperfusion injury, such as renal transplantation, are discussed. Exploring signalling pathways of the SDF-1/CXCR4 axis will contribute to the development of stem cell therapy so that more clinical problems can be solved. Controlling directional homing of stem cells through the SDF-1/CXCR4 axis is key to improving the efficacy of stem cell therapy for tissue injury. CXCR4 antagonists may also be effective in increasing circulating levels of adult stem cells, thereby exerting beneficial effects on damaged or inflamed tissues in diseases that are currently not treated by standard approaches.

scholarly journals Mesenchymal stem cell expression of stromal cell-derived factor-1β augments bone formation in a model of local regenerative therapy

2014 ◽  
Vol 33 (2) ◽  
pp. 174-184 ◽  
Author(s):  
Samuel Herberg ◽  
Galina Kondrikova ◽  
Khaled A. Hussein ◽  
Maribeth H. Johnson ◽  
Mohammed E. Elsalanty ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Bone Formation ◽  
Stromal Cell ◽  
Regenerative Therapy ◽  
Stromal Cell Derived Factor ◽  
Cell Expression

scholarly journals Preclinical Evaluation of the Engineered Stem Cell Chemokine Stromal Cell–Derived Factor 1α Analog in a Translational Ovine Myocardial Infarction Model

2014 ◽  
Vol 114 (4) ◽  
pp. 650-659 ◽  
Author(s):  
John W. MacArthur ◽  
Jeffrey E. Cohen ◽  
Jeremy R. McGarvey ◽  
Yasuhiro Shudo ◽  
Jay B. Patel ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Stem Cell ◽  
Stromal Cell ◽  
Preclinical Evaluation ◽  
Stromal Cell Derived Factor
Sign in / Sign up

Export Citation Format

Share Document